+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06647069

Open-label Phase 1 Study of SAR448501DR-0201 in Adults With Select Autoimmune Rheumatic Diseases including SLE and RA

Led by Sanofi · Updated on 2026-10-21

62

Participants Needed

8

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and activity of SAR448501DR-0201, a bispecific antibody, in adults with select autoimmune rheumatic diseases including systemic lupus erythematosus SLE and rheumatoid arthritis RA. This open-label, phase 1 study aims to find optimal doses by assessing pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical response. Participants will receive SAR448501 over a treatment period lasting up to 71 days, with multiple ascending dose levels studied across different cohorts. The study includes a screening period of up to 28 days before treatment and a follow-up period lasting 42 weeks after treatment ends. If needed, participants will continue to have visits every 4 weeks after the study until specific blood cell levels return to a set threshold. During the study, participants will undergo evaluations of adverse events and clinical responses up to 52 weeks. Researchers will measure drug levels in the blood, immune reactions, and disease activity markers. Safety monitoring includes ongoing assessments during treatment and follow-up, with a total participation time of about 13 months.

CONDITIONS

Brief Title

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here